Similarly, knock down of eIF3h leads to a concurrent downregulation of only the eIF3k and l subunits, hence observations that eIF3h is highly amplified for example in breast and prostate cancers (147) may imply that changes in the expression levels of eIF3k and l might be also expected, which could cause undesirable changes in expression profiles of numerous mRNAs contributing to malignancy. The gene discussed is EIF3K; the disease is prostate cancer.